(P093) Cesium-131 Brachytherapy in High-Risk and Recurrent Head and Neck (HN) Cancers: Long-Term Results of a Pilot Study

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Compared with prior literature, our study shows comparable rates of survival with a decreased rate of radiation-induced toxicity.

Bhupesh Parashar, Anthony Pham, Dattatreyudu Nori, A. Gabriella Wernicke; Weill Cornell Medical Center

BACKGROUND: The feasibility and efficacy of re-irradiation using contemporary radiation techniques to treat recurrent head and neck cancer have been demonstrated, but the role of brachytherapy is unclear. Here, we describe the use of cesium (Cs)-131 brachytherapy with concurrent salvage surgery in 18 patients.

MATERIALS AND METHODS: Eligible patients underwent maximal gross resection of the tumor with implantation of Cs-131 brachytherapy seeds, delivering a minimum dose of 80 Gy to the tumor bed. Rates of overall survival (OS), locoregional progression-free survival (LRPFS), disease-free survival (DFS), and radiation-induced toxicity were analyzed.

RESULTS: Between 2010 and 2013, a total of 18 patients with 20 implants were enrolled and treated with surgical resection and brachytherapy for the management of locoregional recurrences of head and neck cancer. The majority of histology was squamous cell carcinoma (10 of 18). All but one patient had a history of prior radiation in the area of tumor recurrence. One patient had gross residual disease following surgical resection. Two patients underwent an additional surgical resection and brachytherapy implantation 2 months and 5 months later for local recurrence that developed outside of the treatment volume. A total of 13 patients had previous locoregional recurrence treated with surgical salvage therapy. The total dose following initial definite external beam radiation therapy (RT) ranged from 5,000 cGy to 7,000 cGy. Two patients developed grade 3 toxicity; no grade 4 or 5 complications were observed. With a median follow-up of 38 months (range: 1–44 mo), 11 patients developed another recurrence or progression of head and neck cancer. In 6 of these 10 cases, the failure was locoregional, and in 4 patients, it was isolated distant failure. One patient was found to have simultaneous locoregional and distant progression of disease. The median OS was 15 months, and median DFS was 11 months. The 6-, 12-, and 18-month OS rates in this study were 77%, 71%, and 45%, respectively. The 6-, 12-, and 18-month LRPFS rates in this study in patients were 69%, 62%, and 52%, respectively. The 6-, 12-, and 18-month DFS rates in this study were 57%, 45%, and 37%, respectively.

CONCLUSION: Compared with prior literature, our study shows comparable rates of survival with a decreased rate of radiation-induced toxicity. 

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
Related Content